Verseon Corporation (“Verseon” or the “Company”)
Additional Listing and Total Voting Rights
Verseon, a technology-based pharmaceutical company, announces that application has been made for 19,115 new Common Shares of par value $0.001 each (the “Common Shares”) to be admitted to trading on AIM pursuant to regularly scheduled vesting of the restricted stock units (the "Issuance"). The Issuance is in connection with the Verseon Corporation 2015 Equity Incentive Plan and pursuant to the regularly scheduled vesting of previously granted restricted stock units.
Of the 19,115 Common Shares issued, 7,009 Common Shares have been issued to Dr. Thomas Hecht, Non-Executive Chairman of the Company, in relation to payment of his Director’s fees in the form of restricted stock as has been previously disclosed, totalling 28,037 Common Shares vesting quarterly in equal proportions over a one year period. Following Admission, Dr. Hecht will hold 38,318 Common Shares, representing 0.025% of the Company’s issued share capital.
Of the 19,115 Common Shares issued, 7,731 Common Shares have been issued to Grover Wickersham, Non-Executive Director of the Company, in relation to payment of his Director’s fees in the form of restricted stock as has been previously disclosed, totalling 15,463 Common Shares vesting quarterly in equal proportions over a 6 month period. Following Admission, Mr. Wickersham will hold 7,731 Common Shares, representing 0.005% of the Company’s issued share capital.
The 19,115 new Common Shares issued pursuant to the Issuance will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on 3 February 2017 ("Admission").
Total Voting Rights
Following Admission, the issued share capital of the Company will consist of 151,433,774 Common Shares. The Company does not hold any shares in treasury. Therefore the total number of Common Shares in the Company with voting rights will be 151,433,774. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For further information please contact:
|Arthur Shmurun / Amy Thai||+1 (510) 225 9000|
|Cenkos (NOMAD and Joint Broker)|
|Neil McDonald / Beth McKiernan||+44 (0) 20 7397 8900|
|Cantor Fitzgerald Europe (Joint Broker)|
|Marc Milmo / Phil Davies / Callum Butterfield||+44 (0) 20 7894 7000|
|Mirabaud Securities LLP (Joint Broker)|
|Peter Krens||+44 (0) 20 7321 2508|
For financial and business media enquiries, please contact
|Buchanan Communications Ltd (PR Advisors)|
|Henry Harrison-Topham / Sophie Cowles||+44 (0) 20 7466 5000|
Verseon is committed to growth through innovation, building value for its shareholders while respecting its responsibilities as a good corporate citizen